Abstract
New exciting discoveries have emerged in the field of aggressive lymphomas. A better understanding of the biology of lymphomas has been translated into clinical practice, and new drugs are emerging as a hope for better disease control. In this chapter, we review the new therapies for aggressive lymphomas, like proteasome inhibitors, B-cell receptor signaling inhibitors (Syk, Burton's tyrosine kinase and protein kinase C inhibitors) and mammalian targets of rapamycin. Moreover, a concise review of the new monoclonal antibodies (MoAbs) and their new targets is presented. Immunomodulatory drugs like lenalidomide also have shown potential benefit in patients with aggressive lymphomas. Although more studies are necessary, these drugs will probably be incorporated in the management of aggressive lymphomas, with less toxic, targeted therapy.
Original language | English (US) |
---|---|
Title of host publication | Non-Hodgkin Lymphoma |
Subtitle of host publication | Prognostic Factors and Targets |
Publisher | Springer New York |
Pages | 173-189 |
Number of pages | 17 |
ISBN (Electronic) | 9781461458517 |
ISBN (Print) | 9781461458500 |
DOIs | |
State | Published - Jan 1 2013 |
ASJC Scopus subject areas
- General Medicine